Dr. Harmeet Bedi is a Clinical Assistant Professor and Director of Interventional Pulmonology & Bronchoscopy at Stanford University. His expertise is in minimally invasive techniques used in the diagnosis and treatment of various airway and lung diseases such as lung cancer, benign & malignant airway obstruction, and pleural diseases. He specializes in rigid bronchoscopy, airway stent placement, balloon bronchoplasty, endobronchial ultrasound (EBUS) and navigation bronchoscopy, bronchial thermoplasty, intrabronchial valve (IBV) insertion, and various pleural procedures. He also specializes in a variety of tumor ablative therapies including laser therapy, electrocautery, argon plasma coagulation (APC), brachytherapy, and cryotherapy.
He founded the cone-beam computed tomography (CBCT) - guided bronchoscopy program at Stanford in 2019. CBCT-guided bronchoscopy is a novel and cutting-edge technique which combines bronchoscopy with CT imaging, allowing for improved localization and diagnosis of peripheral lung nodules. Additionally, CBCT-guided bronchoscopy will allow for numerous potential cancer therapies that are currently under development.
Dr. Bedi is a principal investigator and co-investigator on multiple clinical trials related to bronchoscopy, thoracic imaging, pulmonary nodules, and lung cancer. Specifically, he has multiple research interests within the realm of bronchoscopic device innovation and CBCT-guided bronchoscopy.
- Interventional Pulmonology
- Thoracic Oncology
- Airway Obstruction (Tracheal and Bronchial)
- Lung Nodules
- Lung Cancer
- Pleural Disease
- Lung Transplant Complications
- Pulmonary Disease
- Critical Care Medicine
Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Director, Interventional Pulmonology & Bronchoscopy (2021 - Present)
Honors & Awards
Teaching Award, Division of Pulmonary & Critical Care Medicine (2018)
Mentorship Award, Stanford Biodesign Fellowship Program (2018)
Mentorship Award, Stanford Biodesign Fellowship Program (2017)
Boards, Advisory Committees, Professional Organizations
Member, American College of Chest Physicians (2012 - Present)
Member, American Thoracic Society (2012 - Present)
Member, American Association of Bronchology and Interventional Pulmonology (2014 - Present)
Fellowship: Loma Linda University Pulmonary and Critical Care Fellowship (2015) CA
Residency: Loma Linda University Internal Medicine Residency (2012) CA
Fellowship: Henry Ford Health System Dept of Pulmonary and Critical Care Medicine MI
Board Certification, American Association of Bronchology and Interventional Pulmonology, Interventional Pulmonology (2016)
Board Certification, American Board of Internal Medicine, Critical Care Medicine (2015)
Board Certification, American Board of Internal Medicine, Pulmonary Medicine (2014)
Board Certification, American Board of Internal Medicine, Internal Medicine (2012)
Fellowship, Henry Ford Hospital, Interventional Pulmonology (2016)
Fellowship, Loma Linda University, Pulmonary & Critical Care Medicine (2015)
Residency, Loma Linda University, Internal Medicine (2012)
MD, Government Medical College, Patiala (2007)
Predicting Lymph Node Metastasis in Non-Small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.
BACKGROUND: Two models, the Help with the Assessment of Adenopathy in Lung cancer (HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were recently developed to estimate the probability of nodal disease in non-small cell lung cancer (NSCLC) patients as determined by endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA). The objective of this study was to prospectively externally validate both models at multiple centers.RESEARCH QUESTION: Are the HAL and HOMER models valid across multiple centers?STUDY DESIGN AND METHODS: This multicenter prospective observational cohort study enrolled consecutive patients with PET-CT clinical-radiographic stage T1-3, N0-3, M0 NSCLC undergoing EBUS-TBNA staging. HOMER was used to predict the probability of N0 vs. N1 vs. N2 or N3 (N2|3) disease and HAL was used to predict the probability of N2|3 (vs N0 or N1) disease. Model discrimination was assessed using the area under the receiver operating characteristics curve (ROC-AUC) while calibration was assessed using the Brier score, calibration plots, and the Hosmer-Lemeshow test.RESULTS: Thirteen centers enrolled 1,799 patients. HAL and HOMER demonstrated good discrimination: HAL ROC-AUC=0.873 (95%CI 0.856-0.891) and HOMER ROC-AUC=0.837 (95%CI 0.814-0.859) for predicting N1 disease or higher (N1|2|3) and 0.876 (95%CI 0.855-0.897) for predicting N2|3 disease. Brier scores were 0.117 and 0.349 respectively. Calibration plots demonstrated good calibration for both models. For HAL the difference between forecast and observed probability of N2|3 disease was +0.012; for HOMER the difference for N1|2|3 was -0.018 and for N2|3 was +0.002. The Hosmer-Lemeshow test was significant for both models (p=0.034 and 0.002) indicating a small but statistically significant calibration error.INTERPRETATION: HAL and HOMER demonstrated good discrimination and calibration in multiple centers. Although calibration error was present, the magnitude of the error is small, such that the models are informative.
View details for DOI 10.1016/j.chest.2021.04.048
View details for PubMedID 33932466
- Key Highlights from the AABIP Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Chest 2020
AABIP Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters.
Journal of bronchology & interventional pulmonology
BACKGROUND: While the efficacy of Indwelling pleural catheters for palliation of malignant pleural effusions is supported by relatively robust evidence, there is less clarity surrounding the post-insertion management.METHODS: The Trustworthy Consensus-Based Statement approach was utilized to develop unbiased, scientifically valid guidance for the management of patients with malignant effusions treated with indwelling pleural catheters. A comprehensive electronic database search of PubMed was performed based on a priori crafted PICO questions (Population/Intervention/Comparator/Outcomes paradigm). Manual searches of the literature were performed to identify additional relevant literature. Dual screenings at the title, abstract and full text levels were performed. Identified studies were then assessed for quality based on a combination of validated tools. Appropriateness for data pooling and formation of evidence-based recommendations was assessed using predetermined criteria. All panel members participated in development of the final recommendations utilizing the modified Delphi technique.RESULTS: A total of 7 studies were identified for formal quality assessment, all of which were deemed to have a high risk of bias. There was insufficient evidence to allow for data pooling and formation of any evidence-based recommendations. Panel consensus resulted in 11 ungraded consensus-based recommendations.CONCLUSIONS: This manuscript was developed to provide clinicians with guidance on the management of patients with indwelling pleural catheters placed for palliation of malignant pleural effusions. Through a systematic and rigorous process, management suggestions were developed based on the best available evidence with augmentation by expert opinion when necessary. Additionally, these guidelines highlight important gaps in knowledge which require further study.
View details for DOI 10.1097/LBR.0000000000000707
View details for PubMedID 32804745
- COVID-19 Test Correlation Between Nasopharyngeal Swab and Bronchoalveolar Lavage in Asymptomatic Patients. Chest 2020
- Radiology-pathology Correlation in Recovered COVID-19, Demonstrating Organizing Pneumonia. American journal of respiratory and critical care medicine 2020
- Foreign Bodies in the Airway: Endoscopic Methods Interventions in Pulmonary Medicine edited by Diaz-Jimenez, J., Rodriquez, A. Springer. 2018; 2nd: 547–569
Microhemorrhage-associated tissue iron enhances the risk forAspergillus fumigatusinvasion in a mouse model of airway transplantation.
Science translational medicine
2018; 10 (429)
Invasive pulmonary disease due to the moldAspergillus fumigatuscan be life-threatening in lung transplant recipients, but the risk factors remain poorly understood. To study this process, we used a tracheal allograft mouse model that recapitulates large airway changes observed in patients undergoing lung transplantation. We report that microhemorrhage-related iron content may be a major determinant ofA. fumigatusinvasion and, consequently, its virulence. Invasive growth was increased during progressive alloimmune-mediated graft rejection associated with high concentrations of ferric iron in the graft. The role of iron inA. fumigatusinvasive growth was further confirmed by showing that this invasive phenotype was increased in tracheal transplants from donor mice lacking the hemochromatosis gene (Hfe -/- ). The invasive phenotype was also increased in mouse syngrafts treated with topical iron solution and in allograft recipients receiving deferoxamine, a chelator that increases iron bioavailability to the mold. The invasive growth of the iron-intolerantA. fumigatusdouble-knockout mutant (ΔsreA/ΔcccA) was lower than that of the wild-type mold. Alloimmune-mediated microvascular damage and iron overload did not appear to impair the host's immune response. In human lung transplant recipients, positive staining for iron in lung transplant tissue was more commonly seen in endobronchial biopsy sections from transplanted airways than in biopsies from the patients' own airways. Collectively, these data identify iron as a major determinant ofA. fumigatusinvasive growth and a potential target to treat or preventA. fumigatusinfections in lung transplant patients.
View details for PubMedID 29467298
Innovative use of a Montgomery cannula in the bronchoscopic management of tracheal stenosis and failed tracheostomy decannulation.
Respiratory medicine case reports
2017; 22: 130–32
Endoprosthesis are being used in the everyday clinical practice either as a permanent solution or transient. They can be used in both benign and malignant situations.We report a case in which a temporary Montgomery cannula is used in conjunction with therapeutic bronchoscopy to manage a patient with failed tracheostomy decannulation secondary to a distal complex tracheal stenosis.This innovative use of the Montgomery cannula allowed for successful management of the patient's tracheal stenosis and subsequent tracheostomy tube decannulation.
View details for PubMedID 28794964
View details for PubMedCentralID PMC5547240
A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer (HAL).
American journal of respiratory and critical care medicine
Estimating the probability of finding N2 or N3 (prN2/3) malignant nodal disease on EBUS-TBNA in patients with non-small cell lung cancer (NSCLC) can facilitate the selection of subsequent management strategies.The goal of this study was to develop a clinical prediction model for estimating the prN2/3.We used the AQuIRE registry to identify patients with NSCLC with clinical radiographic stage T1-3, N0-3, M0 disease that had EBUS-TBNA for staging. The dependent variable was the presence of N2 or N3 disease (vs. N0 or N1) as assessed by EBUS-TBNA. Univariate followed by multivariable logistic regression analysis was used to develop a parsimonious clinical prediction model to estimate prN2/3. External validation was performed using data from three other hospitals.The model derivation cohort (n=633) had a 25% prevalence of malignant N2 or N3 disease. Younger age, central location, adenocarcinoma histology, and higher PET-CT N stage were associated with a higher prN2/3. Area under the ROC curve was 0.85 (95% CI, 0.82-0.89), model fit was acceptable (Hosmer-Lemeshow p=0.62, Brier score 0.125). We externally validated the model in 722 patients. Area under the ROC curve was 0.88 (95% CI, 0.85-0.90). Calibration using the general calibration model method resulted in acceptable goodness of fit (Hosmer-Lemeshow test p=0.54, Brier score 0.132).Our prediction rule can be used to estimate prN2/3 in patients with NSCLC. The model has the potential to facilitate clinical decision making in the staging of NSCLC.
View details for PubMedID 28002683
Bronchoscopist-directed Continuous Propofol Infusion for Targeting Moderate Sedation During Endobronchial Ultrasound Bronchoscopy: A Practical and Effective Protocol.
Journal of bronchology & interventional pulmonology
2015; 22 (3): 226-236
Propofol use for sedation during routine flexible bronchoscopy is expanding. However, there are concerns over propofol's reliability in targeting moderate sedation during more complex and lengthy procedures, such as endobronchial ultrasound (EBUS) bronchoscopy. Its delivery by continuous infusion, which provides a steady sedation effect, may be a practical model for achieving reliable outcomes in this setting.We tested a continuous propofol infusion protocol targeting moderate sedation for EBUS bronchoscopy. A fixed loading rate of 125 mcg/kg/min and initial maintenance rate of 75 mcg/kg/min were used. Sedation assessments were performed every 2.5 minutes. The infusion was adjusted by a nurse under the direction of the bronchoscopist to maintain moderate sedation, normal vital signs, and patient comfort. Prospectively collected data from the first 31 patients using the protocol were analyzed.A mix of EBUS types was performed in a fellowship training environment. Median procedure duration was 51 minutes (interquartile range, 41 to 75 min). Ninety-four percent of total bronchoscopy time was spent in moderate sedation, whereas only 1.9% was occupied by agitation-related delays. Average propofol dose per case was 0.07 mg/kg/min (±0.020), and infusion adjustments were required once every 8 minutes. Sampling goals were met in all patients, and diagnostic and nodal staging accuracies were 90% and 91%, respectively. All tumor specimens sent for genetics were sufficient for analysis. There were no major procedure-related complications.Bronchoscopist-directed continuous propofol infusion is effective and practical for reliably and safely targeting moderate sedation during EBUS bronchoscopy, without sacrificing the breadth and accuracy of the procedure.
View details for DOI 10.1097/LBR.0000000000000187
View details for PubMedID 26165893
Identification of Early Acute Lung Injury at Initial Evaluation in an Acute Care Setting Prior to the Onset of Respiratory Failure
2009; 135 (4): 936-943
Despite being a focus of intensive investigation, acute lung injury (ALI) remains a major cause of morbidity and mortality. However, the current consensus definition impedes identification of patients with ALI before they require mechanical ventilation. To establish a definition of early ALI (EALI), we carried out a prospective cohort study to identify clinical predictors of progression to ALI.Potential cases of EALI were identified by daily screening of chest radiographs (CXRs) for all adult emergency department and new medicine service admissions at Stanford University Hospital.Of 1,935 screened patients with abnormal CXRs, we enrolled 100 patients admitted with bilateral opacities present < 7 days and not due exclusively to left atrial hypertension. A total of 33 of these 100 patients progressed to ALI requiring mechanical ventilation during their hospitalization. Progression to ALI was associated with immunosuppression, the modified Rapid Emergency Medicine Score, airspace opacities beyond the bases, systemic inflammatory response syndrome, and the initial oxygen requirement (> 2 L/min). On multivariate analysis, only an initial oxygen requirement > 2 L/min predicted progression to ALI (odds ratio, 8.1; 95% confidence interval, 2.7 to 24.5). A clinical diagnosis of EALI, defined by hospital admission with bilateral opacities on CXR not exclusively due to left atrial hypertension and an initial oxygen requirement of > 2 L/min, was 73% sensitive and 79% specific for progression to ALI.A new clinical definition of EALI may have value in identifying patients with ALI early in their disease course.
View details for DOI 10.1378/chest.08-2346
View details for Web of Science ID 000265113800012
View details for PubMedID 19188549
View details for PubMedCentralID PMC2758305